KCB-328 (C&C Research Labs).
C & C Research Labs is investigating the class III antiarrhythmic KCB-328 as a potential treatment for heart arrhythmia [310688]. The compound is potent in vitro, with little reverse frequency-dependence when compared with E-4031 (qv) and dofetilide (qv) [223384]. KCB-328 is in preclinical development [351687].